Biopharmaceutical company ADMA Biologics, Inc. (ADMA) announced Monday the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for ASCENIV.
The FDA approval represents the final study report for the Pediatric assessment as required in the post marketing commitment.
Additionally, the approval provides for a revision of ASCENIVs prescribing information to expand the primary humoral immunodeficiency (PI) indication to pediatric patients two years of age and older.
Previously, the indication for ASCENIV was restricted to PI patients aged 12 years and older.
This expanded label for ASCENIV allows ADMA to actively address the treatment needs of younger PI and immune compromised patients earlier in their treatment journey.
In Monday's pre-market trading, ADMA is trading on the Nasdaq at $10.70, up $0.18 or 1.71 percent.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.